Health ❯ Healthcare ❯ Oncology

Melanoma

Immunotherapy Adjuvant Therapy Vaccines Immune Checkpoint Inhibitors Advanced Melanoma BRAF-targeted Therapy Tumor-Infiltrating Lymphocytes Treatment Options Oncolytic Therapies T-Cell Receptor T-Cells BRAF V600 Mutation Chimeric Antigen Receptor T-Cells Diagnosis mRNA Treatment Neoadjuvant Therapy Treatment Protocols Personalized Medicine Targeted Therapy Lung Cancer Immunotherapy Resistance Keytruda Phase 3 Trials Advanced Melanoma Treatments Drug Approval

Moderna’s Phase 3 Melanoma Win Reprices the Company

Late‑stage success for the personalized vaccine reduces clinical uncertainty for intismeran and has driven a sharp re‑rating of Moderna’s stock while key commercial questions remain.

Moderna and Merck Personalized mRNA Vaccine Cuts Melanoma Recurrence in Phase 3 Readout

FDA Grants Accelerated Approval for RP1 (Tudriqev) With Nivolumab in Advanced Melanoma

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

TIM‑3 Triplet Therapy Shows Promise in Immunotherapy‑Resistant Melanoma Models

FDA Rejects Replimune’s RP1 Melanoma Immunotherapy